Full-Time
Mechanical Engineer
Nanopath
11-50 employees
Point-of-care molecular diagnostics for women's health
No salary listed
Cambridge, MA, USA
In Person
On-site in Cambridge, MA; no remote work.
Bachelor's, Master's
 Mechanical Engineering (1) |
|---|
Get referred to Nanopath
See people who can refer or advise you
- Experience designing mechanisms and mechanical assemblies, ideally in a regulated environment.
- Proficiency in SolidWorks and application of ASME Y14.5 GD&T standards.
- Familiarity with manufacturing processes relevant to mechanisms and assemblies (machining, 3D printing, injection molding, casting, extrusion) with a focus on design for manufacturability and affordability.
- Experience executing ISO 13485 design controls, including design verification testing of module level designs.
- Understanding of fluidic systems and the mechanical interactions between an instrument and a consumable cartridge is a plus.
- Experience with human factors engineering or industrial design for healthcare settings is a plus.
- B.S. or M.S. in Mechanical Engineering or related technical discipline with at least 3 years of industry experience.
- Ability to work on-site in Cambridge, MA.
- Excellent communication and presentation skills, highly organized with demonstrated curiosity, scientific rigor and creative problem-solving.
- Proactive self-starter with eagerness to adapt to a fast-paced, dynamic startup environment.
- Passion for technology translation and willingness to shape Nanopath’s future.
- Support the mechanical design, development, and testing of Nanopath's point-of-care molecular diagnostic reader platform.
- Design, source, build, and test mechanical assemblies and mechanisms, including their interactions with the fluidic cartridge and onboard chemistry.
- Develop mechanisms supporting cartridge engagement, fluid actuation, and instrument motion, with attention to reliability and manufacturability.
- Design, build, and test systems from prototype through commercial module verification.
- Support component sourcing and collaborate with vendors and contract manufacturers on custom and off-the-shelf parts.
- Collaborate with cross-functional teams (systems, electrical, software, assay) to define requirements and ensure robust cartridge-to-instrument integration.
- Execute design controls and design verification testing, and maintain documentation in compliance with ISO 13485.
- Understanding of fluidic systems and the mechanical interactions between an instrument and a consumable cartridge is a plus.
- Experience with human factors engineering or industrial design for healthcare settings is a plus
Nanopath develops a molecular diagnostics platform geared toward women’s health. The system tests patient samples for viral, bacterial, and fungal pathogens without nucleic acid amplification, delivering actionable results during a single office visit. Its emphasis on women’s health, a no-amplification workflow, and roots as a Dartmouth spin-off distinguish it from general diagnostic firms by focusing on on-site, routine screening for female patients. The company aims to become the standard go-to point-of-care system for routine women's health screening, empowering clinicians and patients with rapid, accurate information.
Company Size
11-50
Company Stage
Grant
Total Funding
$14.5M
Headquarters
Cambridge, Massachusetts
Founded
2019
Get referred to Nanopath
See people who can refer or advise you
Simplify's Take
What believers are saying
- Nanopath’s website updated July 28, 2026, showing active team growth and hiring.
- CLP Magazine reported FDA Breakthrough Device designation in November 2025 for cUTI.
- MLSC says Nanopath raised over $20 million follow-on funding and hired ten interns.
What critics are saying
- No FDA clearance exists yet; commercialization stalls without pivotal data in 2026.
- Farnam Street Financial sued Nanopath in 2023; contract disputes distract management and cash.
- Point-of-care diagnostics face entrenched PCR incumbents; reimbursement failure can kill adoption.
What makes Nanopath unique
- Amplification-free molecular diagnostics target 15-minute office-visit results for women’s infectious diseases.
- FDA Breakthrough designation for complicated UTI validates a focused, clinically urgent wedge.
- Mass General Brigham and Dartmouth Health IRB partnerships give real-world specimen access.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Stock Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Conference Attendance Budget
Professional Development Budget
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Total will limit
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 3%START grants help companies turn cutting-edge research into new products, businesses and jobs in Massachusetts
Brigham and Women's Hospital's Crimson Core advances Nanopath's women's health diagnostics platform. * April 28, 2026 The Massachusetts Life Sciences Center (MLSC) is proud to support shared research infrastructure that strengthens discovery, collaboration, and commercialization across the Commonwealth. One example is the Crimson Core at Brigham and Women's Hospital (BWH), led by Drs. Lynn Bry and Georg Gerber, which received $3.3 million in 2022 through the MLSC's Research Infrastructure program. This investment supported a critical resource available to researchers across Massachusetts, providing high-quality biofluid samples and specialized processing services that advance research studies, clinical trials, and translational science through the purchase of computational hardware, an Oxford Nanopore sequencer, updated gnotobiotic mouse equipment, and Bruker NMR probes. Since receiving MLSC support, the Crimson Core has handled nearly 1,000,000 biospecimens, with more than 700,000 released to enable research, demonstrating the scale and statewide impact of this shared scientific infrastructure. The impact extends beyond academia and into commercialization. For an early-stage company like Nanopath, this access was transformational. Nanopath, a 2023 awardee of the MLSC's Massachusetts Next Generation (MassNextGen) Initiative, is a Series A-stage diagnostics company rethinking how diagnostic testing is delivered in clinical settings by delivering actionable molecular results within a single office visit. The company is currently pioneering a novel platform for women's health designed to enable faster test results to improve the diagnosis of infectious diseases where speed and accuracy are critical. Through resources provided by the Crimson Core, Nanopath was able to advance development of its diagnostic platform by accessing hundreds of well-characterized patient biospecimens and the expertise needed to better understand gold-standard diagnostic workflows. This work helped the company generate critical validation data and refine how its technology could integrate into real-world clinical practice. "We were immersed in academic research environment, connected with leading clinicians at BWH, and exposed to state-of-the-art diagnostic technology," said Drs. Alison Burklund and Amogha Tadimety, Nanopath. "The first time we walked into the lab, we were in awe of the capabilities." The ability to work with fresh clinical samples, avoid the cost barriers of commercial biobanks, and collaborate directly within the academic and clinical environment at BWH accelerated both technical validation and strategic decision-making. This helped Nanopath generate key data for the company's research and refine their strategy on how its technology could integrate into existing clinical practices Since engaging with the Crimson Core, Nanopath has raised more than $20 million in follow-on funding and received FDA Breakthrough Device Designation for its diagnostic targeting complicated urinary tract infections. Additionally, the company has received non-dilutive funding and business strategy coaching from industry experts through the MassNextGen Initiative, along with support through the MLSC's Internship Challenge, which has enabled the hiring of 10 interns since 2022. Together, MLSC-supported research infrastructure and programming for early-stage companies has driven Nanopath's development momentum, underscoring the role of shared resources like the Crimson Core in translating scientific innovation into real-world impact for patients and enabling faster transitions from discovery to impact. Success Stories Featured in The Beat
Nanopath, a point-of-care diagnostics company, has received $4 million in federal grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF). This funding is intended to support the development of...
Nanopath Inc., a molecular diagnostics company enabling high-quality molecular testing in minutes, announced today that it has closed $10 million in Series A funding, co-led by Norwest Venture Partners and the Medtech Convergence Fund, a SV Health Investors venture fund, with participation from Gingerbread Capital and Green D Ventures.